Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial

Table 2 Treatment-related grade ≥ 2 adverse events

	Dose level	1 n = 1	2 n = 2	3 n = 0	4 n = 1	5 n = 6	6 n = 4	7 n = 3	8 n = 19	Total N = 36
	Bevacizumab IV q2w (mg/kg)	2.5	5	5	5	7.5	7.5	7.5	10
	Cetuximab IV weekly (mg/m²)*	100, 75	100, 75	200, 125	200, 125	200, 125	400, 250	400, 250	400, 250
	Erlotinib PO daily (mg)	50	50	50	100	100	100	150	150
Rash
Grade 2		0	0	0	1	3	2	0	10	16 (44%)
Grade 3		0	0	0	0	0	0	0	4	4 (11%)
Pruritus
Grade 2		0	0	0	1	0	0	0	1	2 (6%)
Grade 3		0	0	0	0	0	0	0	1	2 (6%)
Diarrhea
Grade 2		0	0	0	0	0	0	0	3	3 (8%)
Fatigue
Grade 2		0	0	0	0	1	0	1	0	2 (6%)
Hand-foot syndrome
Grade 2		0	0	0	0	0	0	1	0	2 (6%)
Hypomagnesemia
Grade 2		0	0	0	0	0	0	0	2	2 (6%)
Grade 3–4		0	0	0	0	1	0	0	3	4 (11%)
Nausea/vomiting
Grade 2		0	0	0	0	0	0	0	1	1 (3%)
Mucositis
Grade 2		0	0	0	0	0	0	0	1	1 (3%)
Anorexia
Grade 2		0	0	0	0	0	0	0	2	2 (6%)
Hypertension
Grade 2		0	0	0	0	0	0	0	1	1 (3%)
Bleeding
Grade 3		0	0	0	0	1	0	0	2	3 (8%)
Elevated AST/ALT
Grade 3		0	0	0	0	0	0	0	1	1 (3%)
Anemia
Grade 3		0	0	0	0	1	0	0	0	1 (3%)
Transvaginal fistula
Grade 4		0	0	0	0	2	0	0	0	2 (6%)

ISSN: 2162-3619